Search results
Showing 361 to 375 of 571 results for pregnancy
Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)
Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making
This guidance has been updated and replaced by NICE technology appraisal guidance 156.
NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .
Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)
NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)
NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
Contraception: LARC for people using emergency contraception (IND149)
This indicator covers the percentage of women, on the register, prescribed emergency hormonal contraception 1 or more times in the preceding 12 months by the contractor who have received information from the contractor about long acting reversible methods of contraception at the time of or within 1 month of the prescription. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM115
Contraception: LARC for people on oral or patch contraceptives (IND148)
This indicator covers the percentage of women, on the register, prescribed an oral or patch contraceptive method in the preceding 12 months who have also received information from the contractor about long acting reversible methods of contraception in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM114
Evidence-based recommendations on intraoperative blood cell salvage in obstetrics. This involves filtering and washing shed blood and retransfusing it during or after the procedure.
View recommendations for HTG90Show all sections
Sections for HTG90
This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.
This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
VEST external stent for coronary artery bypass grafts (MIB115)
NICE has developed a medtech innovation briefing (MIB) on the VEST external stent for coronary artery bypass grafts .
This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.
View quality statements for QS49Show all sections
Sections for QS49
- Quality statements
- Quality statement 1: Personal preparation for surgery
- Quality statement 2: Antibiotic prophylaxis
- Quality statement 3: Patient temperature
- Quality statement 4: Intraoperative staff practices
- Quality statement 5: Information and advice on wound care
- Quality statement 6: Treatment of surgical site infection
- Quality statement 7: Surveillance
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.